Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04862221 · ClinicalTrials.gov registry record · Phase 2
TReatment for ImmUne Mediated PathopHysiology
A Phase 2 study of Hepatic Encephalopathy and Immune Dysregulation, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT04862221 is a Phase 2 study of Hepatic Encephalopathy and Immune Dysregulation that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 163 participants, roughly in line with the 163-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT04862221, a Phase 2 study of Hepatic Encephalopathy and Immune Dysregulation, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Conditions Studied
Interventions
- DRUG Prednisolone
- DRUG High-dose methylprednisolone
- DRUG Equine anti-thymocyte globulin
- DRUG Placebo for prednisolone
- DRUG Placebo for infusions
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital - Palo Alto
- Rady Children's Hospital - San Diego
- University of California San Francisco Benioff Children's Hospital - San Francisco
Missouri
- The Children's Mercy Hospital - Kansas City
- St. Louis Children's Hospital - St Louis
New York
- The Mount Sinai Medical Center - New York
- NYP Morgan Stanley Children's Hospital - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Children's - Cleveland
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
Colorado
- Children's Hospital Colorado - Aurora
Connecticut
- Yale New Haven Children's Hospital - New Haven
Georgia
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-02-09 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04862221
The ClinicalTrials.gov registry entry for NCT04862221 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 163-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 5 interventions - of which Prednisolone is the first listed.
NCT04862221 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT04862221 about?
NCT04862221 is a clinical study titled "TReatment for ImmUne Mediated PathopHysiology". TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte g...
What is the current status of trial NCT04862221?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2022-02-09. Estimated completion is 2027-02.
What conditions does trial NCT04862221 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy, Immune Dysregulation, Acute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury.
What interventions are being tested in trial NCT04862221?
The interventions under investigation include: Prednisolone (DRUG), High-dose methylprednisolone (DRUG), Equine anti-thymocyte globulin (DRUG), Placebo for prednisolone (DRUG), Placebo for infusions (DRUG).
Who is sponsoring clinical trial NCT04862221?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04862221 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
COMPLETED · Phase 2
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
-
Affect of Melatonin on Sleep and Cognition in Cirrhosis
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.